Proleukin in Combination With Rituxan in Patients With Low-Grade Non-Hodgkin's Lymphoma Who Have Previously Failed Rituxan Treatments
NCT ID: NCT00045877
Last Updated: 2006-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant Human Interleukin-2 and Rituximab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
Exclusion:
* Subjects who showed no tumor response or a response lasting \<6 months to treatment with Rituximab in combination with Chemotherapy or another therapeutic modality (radiation or radioimmunoconjugates).
* HIV positive.
* Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
* Clinically significant cardiac, pulmonary, and /or hepatic dysfunction (if subject has history of congestive heart failure or myocardial infarction, must have been stable for at least 6 months, and have no current symptoms
* If cardiac ejection fraction has been measured, it must be greater than 50%.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiron Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
California Oncology of the Central Valley
Fresno, California, United States
Virginia K. Crosson Cancer Center
Fullerton, California, United States
Pacific Shores Medical Group
Glendale, California, United States
Wilshire Oncology Medical Group
Glendora, California, United States
California Cancer Care Inc.
Greenbrae, California, United States
Pacific Shores Medical Group
Huntington Beach, California, United States
Santa Barbara Hematology Oncology Medical Group
Lompoc, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
Pacific Shores Medical Group
Los Alamitos, California, United States
UCLS Medical Center
Los Angeles, California, United States
Facey Medical Foundation
Mission Hills, California, United States
North Valley Hematology-Oncology Medical Group
Mission Hills, California, United States
Hoag Cancer Center
Newport Beach, California, United States
North Valley Hematology/Oncology Medical Group
Northridge, California, United States
Ventura County Hematology-Oncology Specialists
Oxnard, California, United States
UCLA Medical Group/Pasadena Oncology
Pasadena, California, United States
Wilshire Oncology Medical Group
Pasadena, California, United States
Wilshire Oncology Medical Group
Pomona, California, United States
Southwest Cancer Care
Poway, California, United States
Wilshire Oncology Medical Group
Rancho Cucamonga, California, United States
Cancer Care Associates Meidcal Group, Inc.
Redondo Beach, California, United States
UC Davis Cancer Center
Sacramento, California, United States
Sansum Santa Barbara Foundation Medical Clinic
Santa Barbara, California, United States
Santa Barbara Hematology Oncology Medical Group, Inc.
Santa Barbara, California, United States
Santa Barbara Hematology Oncology Medical Group
Santa Maria, California, United States
John Wayne Cancer Institute
Santa Monica, California, United States
Santa Barbara Hematology Oncology Medical Group
Solvang, California, United States
Cancer Care Associates Medical Group, Inc.
Torrance, California, United States
UCLA/Santa Clarita Valley Cancer Center
Valencia, California, United States
Ventura County Hematology-Oncology Specialists
Ventura, California, United States
San Diego Cancer Center Medical Group
Vista, California, United States
Wilshire Oncology Medical Group
West Covina, California, United States
Whittingham Cancer Center
Norwalk, Connecticut, United States
Division of Hematology/Oncology, University of Miami, School of Medicine
Miami, Florida, United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, United States
Northwestern University Medical School
Chicago, Illinois, United States
Oncology Specialists,S.C.
Park Ridge, Illinois, United States
Cancer Care Center
Bloomington, Indiana, United States
Indiana Oncology and Hematology Consultants
Indianapolis, Indiana, United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
Hematology and Oncology Specialists, LLC
New Orleans, Louisiana, United States
Louisiana State University Health Sciences Center and VA
Shreveport, Louisiana, United States
Maine Center for Cancer Medicine & Blood Disorders
Scarborough, Maine, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
Benefis Healthcare
Great Falls, Montana, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, United States
Northern New Jersey Cancer Associates
Hackensack, New Jersey, United States
Erie County Medical Center
Buffalo, New York, United States
Advanced Oncology Associates
New Rochelle, New York, United States
Weill Medical College of Cornell University/New York Presbyterian Hospital
New York, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
East Carolina University School of Medicine, Department of Medicine, Division of Hematology/Oncology
Greenville, North Carolina, United States
Gabrail Cancer Center
Canton, Ohio, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio, United States
Hematology Oncology Consultants, Inc.
Columbus, Ohio, United States
Oregon Health & Science University
Portland, Oregon, United States
Cancer Centers of the Carolinas
Greenville, South Carolina, United States
Germantown Cancer Foundation
Germantown, Tennessee, United States
Fletcher Allen Health Care
Burlington, Vermont, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IL2NHL03
Identifier Type: -
Identifier Source: org_study_id
NCT00066534
Identifier Type: -
Identifier Source: nct_alias